Prestige Brands Revs Up Goody’s, BC Brands

Prestige Brands is promoting Goody’s Headache Relief Shot through a deal with NASCAR and its first TV ad on ESPN. Goody’s has paved the way for further expansion into convenience stores, the company says during a sales and earnings call Nov. 7.

Prestige Brands Holdings Inc. emphasizes rapid relief in new marketing for Goody’s and BC pain relievers, which are opening doors for the firm to bring its other lines to convenience stores.

More from United States

Will They Or Won’t They? Tariff Questions Loom For Drugmakers

 

Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.

CDRH Staff Cuts Focus On Administrative Workers, Spare Reviewers

 

One CDRH employee said the cuts already are having a major effect on morale.

Updated: US Likely To Lose Its First Approver Advantage After FDA Layoffs

Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.

PBMs Must Prepare For Revival Of Drug Price Transparency Requirements

 

Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.

More from North America

Is Optum Rx Payment Remodel To Favor Generics A Peace Offering For US FTC?

 

Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Updated: US FDA Commissioner Makary Was Sworn In, Knew Of Plan to Push Out Marks, Sources Say

 

FDA Commissioner Martin Makary was sworn in Friday and knew of the plan that ultimately lead to CBER director Peter Marks' resignation on 28 March.

Peter Marks Resigns From US FDA, Warns Kennedy Does Not Want Truth On Vaccines

 

In his resignation letter, the CBER director said he was willing to work with HHS Secretary Robert F. Kennedy Jr. to address concerns about vaccine safety, but "it has become clear that truth and transparency are not desired by the secretary."